Pseudobutyrivibrio

Most of what your gut bacteria do for you, they do by fermenting fiber. One of the main products is butyrate, a short fatty acid that the cells lining your colon burn for energy and that helps keep the gut wall sealed. Pseudobutyrivibrio is one of the genera that makes it.

When this genus is depleted, it shows up alongside other problems: worse kidney function, more gut-derived toxins in the blood, more small-vessel damage in the brain. Whether the bacteria drive any of that or simply reflect it is unsettled, and that limit shapes how to read your result.

What the Test Actually Measures

The assay amplifies bacterial DNA from your stool sample and reports how much of it belongs to this genus. It counts genetic material. That is not the same as measuring butyrate, and it says nothing about whether the bacteria in your gut are actively fermenting anything.

That distinction matters more than it sounds. Nearly all the published human evidence on Pseudobutyrivibrio comes from 16S rRNA gene sequencing, a research method that profiles the whole bacterial community at once and reports each genus as a percentage of the total. A targeted PCR panel is a different instrument aimed at the same organism. The biology is the same; the numbers are not interchangeable, and there is no cross-platform standard that lets you compare one lab's percentage to another's.

Pseudobutyrivibrio belongs to the Lachnospiraceae family, a large group of gut bacteria that break down dietary fiber into short-chain fatty acids. Two named species show up most in the literature: Pseudobutyrivibrio xylanivorans, which specializes in breaking down xylan from plant cell walls, and Pseudobutyrivibrio ruminis. A genus-level stool test does not tell you which one you carry.

Kidney Disease and Gut-Derived Toxins

The kidney work is the strongest evidence there is for this genus. In a study of 220 people spanning healthy controls, chronic kidney disease at several stages, and peritoneal dialysis, this genus fell in a stepwise way as kidney function declined. It was most abundant in healthy participants and most depleted in advanced renal failure.

The same study went looking for a mechanism. It identified a handful of genera, this one among them, whose abundance correlated with blood levels of indoxyl sulfate and p-cresyl sulfate, toxins your gut bacteria generate from dietary protein and your kidneys are supposed to clear. The published report describes that correlation across a set of genera rather than pinning down the direction for this one on its own, so the gut-kidney mechanism is plausible here rather than established.

As a discriminator it held up reasonably. This genus, alongside Paraprevotella and Collinsella stercoris, separated people with chronic kidney disease from healthy controls better than the urine protein-to-creatinine ratio, a standard clinical kidney marker, and did so even in early-stage disease. The pattern then held in a separate dialysis cohort. No stand-alone accuracy figure for this genus by itself is reported. That is a cross-sectional finding in one study, not a screening trial, and it has not been replicated as a stand-alone test.

If your kidney labs are borderline and this genus reads low, treat it as a prompt to check kidney function properly, not as a diagnosis. Cystatin C and creatinine-based filtration estimates are the tests that actually answer the question.

Brain Small-Vessel Health

In 972 participants of the Framingham Heart Study, higher abundance of this genus tracked with fewer white matter changes on brain MRI, the kind of damage to tiny blood vessels that accumulates quietly with age. The same participants scored better on tests of executive function, the mental work of planning, switching tasks, and holding a goal in mind. This was a secondary association in that paper. Its headline finding concerned a different organism, Barnesiella intestinihominis.

This was a snapshot, taken at one point in time. Nobody was followed forward to see whether people with lower abundance went on to develop more vascular brain damage or cognitive decline. Diet drives both gut composition and vascular health, so a shared upstream cause is entirely possible.

Neurological and Autoimmune Conditions

Depletion of this genus has been reported across a scattered set of conditions, which is itself informative. In Parkinson's disease, it has been reported as reduced alongside broader disruptions in stool short-chain fatty acids, and depletion of butyrate producers generally is a repeated finding in Parkinson's across multiple studies and reviews. Single studies have also reported it lower in autoimmune hepatitis and in psoriatic arthritis, and lower in children with food allergy than in healthy children. The broader pattern of depleted fiber fermenters in these inflammatory conditions is well established; the genus-level specifics rest on individual reports that have not been independently replicated.

Notice what these have in common: they are chronic inflammatory conditions, and they are unrelated to each other. A marker that drops in Parkinson's, kidney failure, autoimmune liver disease, arthritis, and spinal cord injury is not specific to any one of them. In a study comparing 30 people with spinal cord injury to healthy controls, this genus was depleted whichever pattern of bowel dysfunction the injury caused, which tells you that bowel transit and mobility alone can move it.

The reasonable reading is that this genus, like other butyrate producers, tends to fall whenever the gut environment shifts away from fiber fermentation. It is a general indicator of that shift, not a fingerprint of any particular disease.

Why a Low Result Is Not a Diagnosis

Nothing above is a reason to skip the test. It is a reason to interpret it as an indicator rather than an answer. A low reading tells you that one fiber-fermenting group is thin in a single stool sample on a single day. It does not tell you that you have kidney disease, that your brain vessels are damaged, or that you are heading toward Parkinson's.

The broader butyrate-producer literature gives the finding more weight than this genus alone would. In two European population cohorts totaling 10,699 people, higher colonization with butyrate-producing bacteria was linked to a lower risk of being hospitalized for an infection: roughly a quarter lower risk in one cohort and about a seventh lower in the other, per 10% increase in butyrate producers. That is a hard outcome in a large population study, and it is about the functional group, not this genus specifically. It supports the general idea that butyrate production matters; it does not make your Pseudobutyrivibrio number a predictor of your infection risk.

What Can Throw the Number Off

Gut composition moves. A few days of unusual eating, a recent course of antibiotics, a bout of diarrhea, or a change in bowel transit can shift the percentages on a stool panel without anything meaningful changing about your long-term gut function. Antibiotic recovery in particular varies enormously between people, and some beneficial groups stay suppressed for a long stretch afterward.

• Recent antibiotics: any course within the past several weeks can flatten fiber-fermenting genera. Wait at least a month after finishing before testing, or the result tells you about the antibiotic rather than about you.
• Short-term diet swings: a low-fiber travel week or a stretch of eating out will shift the community. Sample during a week that looks like your normal eating.
• Bowel transit: slow or fast transit changes the fermentation environment. Constipation and diarrhea both distort the picture.
• Lab and method differences: DNA extraction kits, the region of the bacterial gene targeted, and the sequencing or PCR platform all change the number reported. Do not compare a result from one lab against a result from another.

Why One Reading Is Not Enough

For this marker more than most, the trend is the whole point. There is no published reference interval and no clinical cutoff for Pseudobutyrivibrio in stool. Without a threshold, a single number in isolation has nowhere to anchor. Your own prior result is the only comparison that means anything.

Responses to any given intervention are also strongly person-dependent. The same fiber that lifts butyrate production in one person does nothing in another, depending on which organisms they started with. That is exactly why tracking your own baseline beats reading a population average.

Get a baseline. Retest in three to six months if you are changing your diet or recovering from antibiotics, then at least annually. Sample under consistent conditions each time: same lab, same method, a normal eating week, well away from any antibiotic course. A consistent downward drift across several readings under matched conditions is worth investigating. A single low number is not.

What to Do With an Unexpected Result

Read this genus in context, not alone. It is one line on a panel, and the panel as a whole carries more signal than any single genus. Look first at whether the other fiber-fermenting organisms on your report moved in the same direction. If Faecalibacterium prausnitzii, Roseburia, and Butyrivibrio crossotus are all down together, that is a coherent picture of reduced fiber fermentation. If this one genus is low while the rest look normal, the most likely explanation is sampling noise.

Then look at what the panel measures functionally. Stool short-chain fatty acids, particularly butyrate, tell you whether fermentation is actually producing the compound in question rather than just whether the bacteria are present. Fecal calprotectin tells you whether the gut lining is inflamed. Those two together separate a quiet, low-fermentation gut from an actively inflamed one, and the distinction changes what you do next.

If the pattern is broad butyrate-producer depletion plus elevated calprotectin plus real digestive symptoms, that combination warrants a gastroenterologist and a proper workup, not a supplement. If you have any reason to suspect kidney involvement, borderline creatinine, a family history, high blood pressure, or diabetes, order cystatin C and a creatinine-based filtration estimate. Those answer the kidney question directly; this test only hints at it.

If everything else looks normal and you feel fine, the right move is to retest under controlled conditions in a few months and watch the trajectory.